What are antitumour drugs, really?
"Chemotherapy" sounds like a single thing and is actually a whole arsenal. More than a hundred individual agents, grouped into at least five very different mechanism families, all sharing one job: stopping a tumour cell from dividing, or pushing it into a controlled form of suicide called apoptosis. That is the entire definition. Everything else — the brand names, the regimens, the schedules — is detail piled on top of that one idea.
The umbrella term on pharmacy stickers and import declarations is antineoplastic, "against new growth". Doctors say cytotoxic ("cell-killing") for classical chemotherapy and cytostatic ("cell-stopping") for drugs that pause division. Not synonyms, but they live next door on the shelf.
Inside that umbrella, the families that matter for almost any patient travelling on treatment are:
- Alkylating agents — cyclophosphamide (Cytoxan, Endoxan), ifosfamide, melphalan
- Antimetabolites — methotrexate, 5-fluorouracil (Adrucil), capecitabine (Xeloda), gemcitabine (Gemzar)
- Anti-microtubule agents — paclitaxel (Taxol), docetaxel (Taxotere), vincristine
- Platinum compounds — cisplatin (Platinol), carboplatin (Paraplatin), oxaliplatin (Eloxatin)
- Anthracyclines — doxorubicin (Adriamycin), epirubicin
- Targeted therapy — imatinib (Gleevec), trastuzumab (Herceptin), erlotinib (Tarceva), bevacizumab (Avastin)
Why does this matter to you as a reader? Because if you are continuing oncology therapy across a border, the family is the level at which a foreign doctor or pharmacist can actually help you. "I'm on chemotherapy" tells them nothing. "I'm on FOLFOX — 5-fluorouracil, leucovorin, oxaliplatin, last cycle two weeks ago" tells them everything: mechanisms, expected blood counts, the side-effect window, emergencies to watch for.
Unlike the NSAIDs or proton pump inhibitors, cytotoxics are not tools you can think about in isolation. The drug, the schedule, the monitoring labs and the supportive medications are a single object.
How they work — the simple version
Cancer is, at the cellular level, division gone unsupervised. Healthy cells have brakes — checkpoints that say "wait, check the DNA, are we sure?" Cancer cells have lost some of those brakes, part of what Hanahan and Weinberg called the hallmarks of cancer (Hanahan & Weinberg, Cell, 2011). The result is a population that keeps copying itself, sometimes with more mutations, sometimes spreading where it has no business being.
Classical chemotherapy was built on one blunt observation from the 1940s, after nitrogen mustard gas survivors turned out to have wrecked bone marrow: chemicals that damage DNA hit fast-dividing cells the hardest (Chabner & Roberts, Nature Reviews Cancer, 2005; DeVita & Chu, Cancer Research, 2008). Cancer cells, on average, divide faster than the cells around them. A DNA-poisoning drug, given carefully, will hurt the tumour more than it hurts the host. That is the entire conceptual foundation of cytotoxic chemotherapy. It is crude, it works often enough to save lives, and it is the reason your hair falls out: the difference between "fast" and "slow" is statistical, not absolute.
Each family attacks the dividing cell at a different point. Picture a cell preparing to split as a small construction site: a blueprint (DNA), workers copying it (enzymes), building materials (nucleotides), and a pulley system (the mitotic spindle) that drags the two new copies apart. Different drugs sabotage different parts of the site:
- Alkylating agents glue the two strands of DNA together with a chemical tag. Imagine someone walking through the construction site with super-glue, fixing pages of the blueprint together. Cyclophosphamide and cisplatin do versions of this.
- Antimetabolites look almost — but not quite — like the building blocks the workers expect. Methotrexate masquerades as folate; 5-fluorouracil masquerades as a uracil base. The workers grab the fake, slot it in, and construction halts. Capecitabine is a 5-FU prodrug the body activates preferentially inside the tumour.
- Taxanes and vinca alkaloids mess with the pulley system. Paclitaxel freezes the microtubules; vincristine prevents them forming. The cell is stuck mid-division and triggers apoptosis. The same microtubules carry molecules along long nerve axons — which is why these drugs cause peripheral neuropathy.
- Platinum compounds form intra- and inter-strand DNA crosslinks. Cisplatin was the first; carboplatin is gentler on the kidneys; oxaliplatin gives the distinctive cold-induced fingertip neuropathy anyone on FOLFOX learns to recognise within a week.
- Anthracyclines like doxorubicin do several things at once — intercalate into DNA, poison topoisomerase II, generate free radicals. The free-radical part is what makes them rough on the heart.
- Targeted therapy broke the "faster-dividing equals more vulnerable" rule. These drugs aim at one specific mutant protein driving one specific tumour. Imatinib blocks BCR-ABL in chronic myeloid leukaemia. Trastuzumab latches onto HER2-overexpressing breast cancer cells. Erlotinib blocks an EGFR mutation in some lung cancers. Scalpels, not hammers — but only if the tumour carries the target. Without it, the drug does nothing.
The two-decade arc from the 1990s to today, traced by Falzone and colleagues (Frontiers in Pharmacology, 2018), is the story of how oncology added a selective targeted-therapy layer on top of the cytotoxic backbone.
What else they do to your body, beyond fighting cancer
This is where the brute-force logic of classical chemotherapy has its bill come due. If your drug attacks rapidly dividing cells in general, then anywhere in your body where cells divide rapidly is going to get hit. There are three big places that qualify, and a short list of family-specific extras.
Bone marrow. Your marrow churns out white cells, platelets and red cells around the clock. Chemotherapy drops those numbers — sometimes a little, sometimes a lot. Low neutrophils is neutropenia, the reason patients are told to avoid crowds and raw food during the nadir. Low platelets is thrombocytopenia — easy bleeding and bruising. Low red cells is anaemia, a wall of fatigue. Not "complications"; the same mechanism that is killing the tumour, just landing in marrow instead.
The gut lining turns over every three to five days — about the rate of many tumours. Hit that population and you get mucositis: mouth sores, painful swallowing, taste changes, diarrhoea, sometimes severe enough to need IV fluids. 5-FU, methotrexate and the taxanes are particularly notorious.
Hair follicles. Matrix cells at the base of a follicle are some of the fastest-dividing cells in the body, which is why alopecia is so visually associated with chemo. Not every regimen causes it — anthracyclines and taxanes almost always do, capecitabine and many targeted agents barely do at all.
Nausea and vomiting come from two routes: direct stimulation of a brainstem region called the area postrema, and gut irritation feeding back through the vagus nerve. Modern antiemetic protocols (5-HT3 antagonists, dexamethasone, NK1 antagonists) have transformed this part of chemotherapy.
A few family-specific extras worth knowing: platinum compounds cause peripheral neuropathy that can outlast treatment by months (cisplatin also damages hearing and kidneys); anthracyclines are cardiotoxic in a cumulative way, with a lifetime ceiling on doxorubicin before heart-failure risk rises sharply; cyclophosphamide can cause haemorrhagic cystitis (mesna is given as a urinary protectant); tyrosine kinase inhibitors like imatinib look mild on paper but routinely cause oedema, muscle cramps and liver enzyme bumps; trastuzumab has its own reversible-but-real cardiac story (the reason patients on it get echocardiograms); EGFR inhibitors cause an acne-like rash that paradoxically often correlates with the drug working; bevacizumab raises blood pressure and occasionally perforates the bowel.
The pattern: the side-effect profile of any antitumour drug is not a random list; it is the same mechanism re-read against a different tissue. Know the family, and you can predict most of what the drug will do to a body.
What people usually take with them, and why
Antitumour drugs are almost never given alone. They live inside regimens — named combinations attacking different cell-cycle phases at once, designed to suppress resistance and squeeze more tumour kill out of the same dose ceilings. NCCN and ESMO guidelines specify which regimen goes with which cancer type, stage and biomarker profile. A short sample:
- CHOP — cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine (Oncovin), prednisolone — the workhorse of diffuse large B-cell lymphoma for decades. Modern protocols add rituximab on top (R-CHOP).
- FOLFOX — 5-fluorouracil, leucovorin and oxaliplatin — first-line for many stages of colorectal cancer.
- AC-T — doxorubicin and cyclophosphamide followed by a taxane — a common backbone in early breast cancer.
- Trastuzumab plus a taxane — standard for HER2-positive breast cancer.
- Carboplatin plus paclitaxel — used across ovarian, lung and several other cancers.
Around the cytotoxic skeleton sits a layer of supportive medications that are not optional decoration. Antiemetics (ondansetron, aprepitant, dexamethasone) are scheduled with each cycle. Granulocyte colony-stimulating factor (G-CSF) is often given the day after chemotherapy to keep the white-cell nadir from getting dangerous. Allopurinol prevents tumour lysis syndrome in highly proliferative cancers. PPIs handle corticosteroid-induced acid rebound.
A short list of interactions:
- CYP3A4 and P-glycoprotein are the highways through which many cytotoxic and targeted drugs are cleared. A "harmless" antibiotic (clarithromycin), a "natural" supplement (St John's wort), even grapefruit juice can shift cytotoxic levels by a factor of two or three. For a drug with a narrow therapeutic window, that is not a footnote.
- Warfarin plus chemotherapy is one of the highest-risk combinations in pharmacy. Switching to low-molecular-weight heparin is often safer, and that decision belongs to the oncologist.
- NSAIDs in a patient with chemo-induced thrombocytopenia compound bleeding risk and stress the kidneys at the worst moment. The NSAIDs article explains why.
- Live vaccines are generally contraindicated during cytotoxic chemotherapy.
- Herbal supplements are not benign — most have not been tested against oncology agents, and several (St John's wort, high-dose antioxidants) have documented harms.
The pattern: combination chemotherapy is a carefully timed system. Adding a drug, dropping a dose, changing a schedule or substituting a "similar" molecule across a border is not an adjustment — it is a redesign. Only the team running your protocol has the visibility to do it safely.
Red flags — when to call a doctor
There is a short list of symptoms during chemotherapy that are not "wait and see" and not "call tomorrow morning". They are go-to-the-emergency-room, and the staff there need to know you are an oncology patient the moment you walk in.
- Fever of 38.0 degrees Celsius (100.4 F) or higher, with or without chills, during the post-chemotherapy window. This is the textbook presentation of neutropenic fever, and it is a potentially life-threatening emergency. ESMO and NCCN guidance is unambiguous: an oncology patient with fever during the nadir is treated as a medical emergency, with broad-spectrum antibiotics started within an hour of arrival. Do not stay home. Do not assume it is just a cold.
- Unexplained bruising, petechiae, nosebleeds that will not stop, or blood in stool or urine. These can indicate low platelets or another cause of bleeding and need urgent assessment.
- Severe mouth pain or mucositis preventing you from eating or drinking. Dehydration in a chemotherapy patient compounds kidney injury fast.
- New shortness of breath, chest pain, palpitations, or swelling in the legs, especially if you have ever received anthracyclines or trastuzumab. Both classes are cardiotoxic and decompensation can be sudden.
- New numbness, tingling or weakness in the hands and feet — common with platinum compounds and taxanes; escalating symptoms can mean permanent neuropathy.
- Severe diarrhoea or persistent vomiting with signs of dehydration.
- A rash that is spreading, blistering or peeling. Particularly with targeted agents and immune-checkpoint inhibitors, severe skin reactions can be life-threatening.
- Confusion, severe headache, slurred speech, weakness on one side of the body. Possible stroke, CNS bleeding or, with some immunotherapies, neurological inflammation.
A separate emergency in the first 24 to 72 hours of treatment for highly proliferative cancers (acute leukaemias, high-grade lymphomas): tumour lysis syndrome, where rapid destruction of cancer cells dumps potassium, phosphate and uric acid into the blood faster than the kidneys can handle. Signs are non-specific (nausea, cramps, palpitations); consequences (arrhythmia, renal failure) are immediate.
If you are travelling on treatment, this is why the carry-on kit matters: protocol on paper, recent labs, oncologist contact, generic and brand names of every drug, dates of last and next cycle. A foreign emergency department can manage neutropenic fever in any country — but only if they know within minutes that you are an oncology patient.
What people get wrong
"Targeted therapy is not real chemotherapy, so it is safe." It is real treatment with real side effects, just different ones. Imatinib causes oedema, muscle cramps and liver enzyme bumps. Trastuzumab causes reversible but real cardiac dysfunction. Bevacizumab raises blood pressure and rarely perforates the bowel. EGFR inhibitors cause a debilitating rash. Immune checkpoint inhibitors can trigger autoimmune inflammation of almost any organ — thyroid, lung, gut, liver, heart. "Targeted" means selective for the cancer's vulnerability, not for the patient's comfort.
"I can skip a cycle to give my body a break." The schedule is not a suggestion. Modern regimens are designed around the growth kinetics of the tumour and the recovery kinetics of bone marrow — the interval is the smallest one that lets normal tissues recover while staying short enough to keep ahead of the cancer. A self-imposed gap lets resistant populations repopulate. If you genuinely cannot tolerate the schedule, the answer is a call to the oncology team — they can dose-reduce, switch antiemetics or change the regimen.
"A generic is a generic, even in oncology." Generic cytotoxics exist and save enormous amounts of money worldwide. The catch is the narrow therapeutic window — minor formulation differences matter more than they would for an over-the-counter painkiller. The swap belongs to an oncologist with monitoring labs in hand, not to you at a foreign pharmacy counter.
"If my hair is not falling out, the drug must not be working." Hair loss is mechanism-driven, not effectiveness-driven. Anthracyclines and taxanes nearly always cause alopecia; capecitabine and most targeted agents usually do not. A bald head says something about the regimen, not about the response. Imaging and tumour markers are how response is measured.
"Antioxidant supplements protect normal cells during chemotherapy." Several chemotherapy mechanisms — anthracyclines, platinum compounds, radiation — work partly by generating oxidative damage inside cancer cells. High-dose antioxidants (vitamin C, vitamin E, NAC) may, in principle, blunt that effect. Clinical data are mixed, but major oncology societies advise against unsupervised high-dose antioxidant supplementation during active treatment. Dietary antioxidants from food, not bottles, while on chemo.
"I'll find the same drug abroad — same molecule, just another label." The most dangerous misconception for the audience this article exists for. The pill is the smallest piece of the protocol. Oncology drugs require scheduled blood counts, imaging, organ-function tests, dose adjustments, supportive medications, and a clinician who can act when a number goes the wrong way. Filling a prescription abroad, even of an identical molecule, separates the drug from its monitoring infrastructure. WHO's Model List of Essential Medicines includes antineoplastics precisely because access matters globally — while making clear they are restricted-distribution drugs requiring specialist oversight.
One takeaway off this page: antitumour drugs are not consumer products. They are part of a system built by an oncology team around your tumour, your labs and your tolerances. If you are travelling on treatment, your job is not to manage the chemotherapy — it is to keep the chain from breaking: carry the protocol, the labs, the contacts. The rest is theirs.